Skip to content
Satellos Bioscience Logo

Satellos Biosciences: Preliminary Data in FSHD and Promising Outlook for Duchenne

February 13, 2024

Satellos Biosciences is developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, including positive preliminary data showing SAT-3247 can improve skeletal muscle function in a mouse model of facioscapulohumeral muscular dystrophy (FSHD).

What does this mean for Duchenne muscular dystrophy?

  • Data support potential for SAT-3247 in multiple degenerative muscle diseases
  • On track to initiate first-in-human clinical trial mid-2024 for Duchenne muscular dystrophy

“These data in FSHD, in combination with our preclinical Duchenne studies, collectively demonstrate the impact of SAT-3247 on improving muscle regeneration in degenerative muscle diseases. We look forward to presenting these data at the MDA Clinical and Scientific Conference 2024 and advancing SAT-3247 into clinical trials for Duchenne muscular dystrophy mid-year.”

Frank Gleeson, Cofounder and CEO of Satellos

What is SAT-3247?

Satellos’s SAT-3247 is a small molecule designed to inhibit AAK1, a protein kinase member of the Notch pathway. The company believes AAK1 inhibition, independent of dystrophin, has the capacity to regulate polarity to restore asymmetric muscle stem cell division, generate muscle progenitor cells, and enable muscle regeneration.

Defeat Duchenne Canada is pleased to be currently funding the work of Dr. Mike Rudnicki, who is the Director of the Regenerative Medicine Program at the Ottawa Research Institute and is also the Chief Scientific Officer of Satellos Bioscience Inc. 

Related Articles